natgillin/translations-raw huggingface dataset:
at each occurrence is independently selected from H, F, Cl, Br, C1-C6 alkyl, C1-C6 and alkyloxy; 
uvijek kada se pojavljuje je neovisno odabran od H, F, Cl, Br, C1-C8 alkila, i C1-C8 alkiloksi;
The method of claim 1, wherein the immunoglobulin Fc polypeptide comprises at least one of the following mutations: Met252Tyr, Ser254Thr, Thr256G1u, Met428Leu or Asn434Ser. 
Izolirani fuzijski protein za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, gdje: a. imunoglobulinski Fc polipeptid je modificiran tako da poboljšava vezivanje FcRn; b. imunoglobulinski Fc polipeptid sadrži najmanje jednu od sljedećih mutacija: Met252Tyr, Ser254Thr, Thr256Glu, Met428Leu ili Asn434Ser.
Plates were then sealed and stored for up to 2 weeks at 4°C. 
Pločice su potom zapečate i pohrane do 2 tjedna pri 4 *C.,
70 0 A composition suitable for control of diseases caused by phytopathogens comprising 
Pripravak koji je pogodan za nadzor bolesti uzrokovanih fitopatogenim organizmima uključujući (A) spoj formule I
Appropriate cosubstrates in a process according to the present invention include, for example, alcohols (e.g., 2-propanol), lactic acid and salts thereof, pyruvic acid and salts thereof, oxygen, hydrogen and/or formic acid and salts thereof. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time, da su ko-supstrati izabrani između alkohola, mliječne kiseline i njihovih soli, piruične kiseline i njihovih soli, kisika, vodika i / ili mravlje kiseline i njihovih soli.
The chimeric polypeptide of claim 1-6, wherein the GPCR is a naturally occurring GPCR, or a variant of a naturally occurring GPCR or a truncated form of a naturally occurring GPCR, wherein the GPCR is preferably chosen from the group comprising a GPCR of the Glutamate family of GPCRs, a GPCR of the Rhodopsin family of GPCRs, a GPCR of the Adhesion family of GPCRs, a GPCR of the Frizzled/Taste2 family of GPCRs, and a GPCR of the Secretin family of GPCRs. 
Himerni polipeptid u skladu s patentnim zahtjevom 1 do 6, naznačen time, da je GPCR prirodno prisutan GPCR ili varijanta prirodnog GPCR-a ili skraćenog oblika prirodnog GPCR-a, pri čemu je GPCR poželjno odabran iz skupine koja sadržava GPCR iz obitelji glutamata GPCR, GPCR iz obitelji Rodopsin GPCR-a, GPCR iz adhezijske obitelji GPCR-a, GPCR „frizzled" /,,Taste2" obitelji GPCR-a i GPCR Secretinove obitelji GPCR-a.
A patient in need of such treatment may be suffering from, e.g., cancer, another proliferative disorder, an infectious disease or an immune disorder. 
Oblik prema zahtjevu 42, gdje taj bolesnik boluje od raka, drugog proliferativnog poremećaja, infektivne bolesti ili imunog poremećaja.
In accordance with a preferred embodiment of the apparatus, the movement restriction device comprises a body adapted to be at least partly invaginated by the patient's stomach fundus wall and having an outer surface that includes a biocompatible material. 
Uređaj u skladu s patentnim zahtjevom 5, naznačen time što je tijelo proširljivo tijelo, prilagođeno da bude invaginirano dijelom stijenke pacijentovog želuca, te što uređaj za rukovanje ima spremnik fluida (16; 46; 52; 90;
A method according to claim 1 or claim 2 wherein the GPR119 agonist has an EC50 of less than 100 nM. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist ima EC50 manji od 100 nM.
at least one actuation device (6) provided in operational connection with said control device (4) and adapted so as to provide at least the actuation of start of a beverage preparation cycle, 
- barem jedan uređaj za pokretanje (6), koji operativno povezan s upravljačkim uređajem (4) 1 prilagođen je tako da omogućuje barem aktiviranje početka ciklusa pripreme napitka,
A process as claimed in claim 16 wherein the amount of guar gum is from 0.1 to 3%. A process as claimed in claim 17 comprising 0.25% to 2.5% guar gum. 
Mrvice prema zahtjevu 15 gdje je količina guar gume od 0.1 do 3%, bolje od 0,25% do 2,5%, još bolje od 0.7% do
The process of claim 1, wherein the ferric chloride is present in the reaction mixture in an amount in the range of from 30 to 1000 ppm. 
Postupak iz patentnog zahtjeva 1, pri čemu je željezov(IlI) klorid prisutan u reakcijskoj smjesi u količini koja je u rasponu od 30 do 1000 ppm.
wherein said domains (D) and (E) do not associate with one another to form an epitope binding site; and wherein: 
pri čemu navedene domene (D) i (E) se ne vežu međusobno tako da formiraju mjesto vezanja epitopa; i pri čemu:
Example 6 In Vitro Human Plasma Stability of GLP-1CM Peptides 
Slika 7 stabilnost GLPI peptida u plazmi (in vitro test)
The process according to claim 1, wherein the Suzuki coupling conditions comprise heating a reaction mixture comprising the compound of Formula IIIa, the compound of Formula IVa, a Suzuki coupling catalyst, a base and a solvent component. The process according to claim 2, wherein the Suzuki coupling catalyst is: 
Postupak prema zahtjevu 1, naznačen time što Suzukijevi uvjeti spajanja obuhvaćaju zagrijavanje reakcijske smjese koja se sastoji od spoja Formule IIIa, spoja Formule IVa, katalizatora Suzukijevog spajanja, baze i komponente otapala.
a C1-6 alkoxy-carbonyl group optionally having 1 to 3 substituents selected from a nonaromatic heterocyclic group optionally having 1 to 3 substituents selected from a C1-6 alkyl group and oxo group, 
C1-6 alkoksi-karbonilna skupina koja opcionalno ima 1 do 3 supstituenta odabrana iz nearomatske heterociklične skupine koja opcionalno ima 1 do 3 supstituenta odabrana iz C1-6 alkilne skupine i okso skupine;
The ET-743 can be of synthetic or semisynthetic origin. 
ET-743 može biti sintetičkog ili polu-sintetičkog porijekla.
loading a cation exchange column with the eluent from the anion exchange column so as to permit capture of the non-complexed botulinum toxin A by the cation exchange column; and 
stavljanja u stupac za anionsku izmjenu eluensa iz stupca za anionsku izmjenu tako da se omogući skupljanje nekompleksiranog botulinskog toksina A u stupcu za kationsku izmjenu; i
The composition of claim 3, wherein said agent is an anti-TGFß antibody. The composition of claim 4, wherein said antibody is a pan neutralizing anti-TGFß antibody. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 4, naznačen time što navedeno protutijelo je pan neutralizirajuće anti-TGFB protutijelo.
A requirement was set that 99% of laser power of 8 W at 980 nm was to be absorbed after passage through a maximum of 2 mm of the elastomer i.e. an absorption coefficient a as defined above of 2 mm−1, optimally 1.5 mm−1. 
Bio je postavljen zahtjev da 99% snage lasera od 8 W kod 980 nm treba biti apsorbirano nakon prolaza kroz maksimalno 2 mm elastomera, to jest da koeficijent apsorpcije a kao što je gore definiran iznosi 2 mm", optimalno 1.5 mm".
The process according to claim 16 wherein the additional isolation of the other diastereoisomeric salt of formula (II) comprises the concentration of the mother liquor generated upon isolating the first diastereoisomeric salt and subsequent crystallization to obtain said other diastereoismeric salt. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se dodatno izdvajanje druge dijastereoizomerne soli formule (II) sastoji u koncentriranju matičnog luga dobivenog prilikom izdvajanja prve dijastereoizomerne soli i kristalizacije nakon toga kako bi se dobilo navedenu drugu dijastereoizomernu sol.
contacting the plasma-derived target protein composition with a chromatographic resin under conditions suitable to bind the plasma-derived target protein; and 
(i) stavljanje u doticaj sastava ciljanog proteina izvedenog iz plazme s kromatografskom smolom pod uvjetima koji su pogodni za vezanje ciljanog proteina izvedenog iz plazme; i
In a further aspect the teaching relates to a method of treating or preventing a disease or disorder involving cells expressing CLD18, preferably CLD18A2, comprising administering to a subject an antibody of the teaching, a conjugate thereof with a therapeutic agent, or a pharmaceutical composition comprising the antibody of the teaching or the conjugate thereof with a therapeutic agent. 
Protutijelo sukladno patentnom zahtjevu 1, konjugat sukladno patentnom zahtjevu 3 ili farmaceutski pripravak sukladno patentnom zahtjevu 4 za uporabu u postupku liječenja ili prevenciju bolesti ili poremećaja koji uključuje stanice koje eksprimiraju CLD18A2.
This annular ring or disk may support the corresponding pressing member or members such that they are moveable in a radial direction. 
Ovaj prstenasti kolut ili disk može imati odgovarajući tlačni element ili tlačne elemente 1 to takve koji se mogu pomicati u radijalnom smjeru.
at least one spring member (5 a) acting between the gripping shanks, against the action of which the gripping shanks (10, 20) are pivotable from the closed position towards the open position, wherein 
- < najmanje jedne opruge (5a) koja djeluje između steznih držača, protivno djelovanju kojim se stezni držači (10, 20) zakreću iz zatvorenog položaja prema otvorenom položaju, naznačen time da:
Formulations as claimed in any one of claims 1 to 8, in the form of water/oil emulsions, soft gelatin capsules, vaginal pessaries or equivalent formulations, creams, ointments, powders, lotions, and the like. 
Formulacije kako su navedene u patentnim zahtjevima 1 do 8, naznačene time da su u obliku voda/ulje emulzija, mekih želatinskih kapsula, vaginalnih krema ili ekvivaletnih formulacija, krema, masti, prašaka, losiona i slično.
4, FIG. 6 is a plan view of the sheet metal strip on termination of the bending stage, 
je pogled s gornje strane na limenu metalnu traku na završetku faze savijanja, slika 7
Preparation of the Rapamycin Carbohydrate Derivatives 
Priprema ugljikohidratnih derivata rapamicina
The apparatus of claim 11, wherein the free layer is positioned a first distance from the drain terminal and the pinned layer is positioned a second distance from the drain terminal, and wherein a conductive path electrically connects the drain terminal to the free layer. 
Uređaj sukladno zahtjevu 11, pri čemu je slobodni sloj smješten na prvoj udaljenosti od odvodnog terminala, i pri čemu vodeći put električno spaja odvodni terminal sa slobodnim slojem.
Example 6 Measurement of pH in Lozenge 
Primjer 6-Mjerenje pH u tableti
wherein said alkyl and aryl groups and heterocyclic ring are optionally substituted with one to three R20 groups; 
pri čemu navedene alkilna i arilna skupina i heterociklički prsten su proizvoljno supstituirani sa jednom do tri R20 skupine;
a controller configured to, for one or more pairs of a source basin and an adjacent recipient basin: 
(d) upravljač (32) konfiguriran na, za jedan ili više parova izvornog bazena i susjedan prijemni bazen:
In an embodiment, the further mobile communication technology is a technology according one of the IEEE-802.11-family of mobile communication standards. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je druga mobilna komunikacijska tehnologija, tehnologija prema jednom iz IEEE 802.11-seta standarda za mobilnu komunikaciju.
reacting an intermediate of formula (VI-a) or (VI-b) wherein W2 represents a suitable leaving group, with a suitable primary or secondary amine HNR4R5, optionally in the presence of a suitable solvent wherein all variables are defined as in claim 1; 
(Ib-2) pri čemu su sve varijable kako je definirano u zahtjevu 1; d) reakcije intermedijera sa formulom (VI-a) ili (VI-b) pri čemu W> predstavlja prikladnu odlaznu skupinu, sa pogodnim primarnim ili sekundarnim aminom HNR*R-, proizvoljno u prisutnosti pogodnog otapala
the composition is a pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solution, dispersion, suspension or emulsion, or a sterile powder which may be reconstituted into sterile injectable solutions or dispersions. 
(ili) pripravak je farmaceutski prihvatljiva sterilna izotonična vodena ili nevodena otopina, disperzija, suspenzija ili emulzija, ili sterilni prašak koji se može rekonstituirati u sterilne injekcijske otopine ili disperzije.
Soft capsules The ingredients below were mixed by an ordinary method and filled in soft capsules. 
Sastojci, niže, pomiješani su uobičajenim postupkom, te napunjeni u meke kapsule.
The antibody-like binding protein of any one of claims 1, 2, 5 or 6, wherein the binding protein is bispecific and capable of binding two different antigen targets, wherein, preferably, the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1a and IL-1B, TNFa and IL12/23, TNFa and IL-12p40, TNFa and IL1B, TNFa and IL-23, and IL17 and IL23. 
Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid je bispecifičan i može vezati dva različita antigenska cilja, pri čemu, poželjno, dva različita antigenska cilja se biraju iz skupine koju čine ILA i 1L13, IGFIR i HER2, IGFIR i EGFR, EGFR i HER2, BK i IL13, PDL-1 i CTLA-4, CTLA4 1 MHC razred II, IL-12 i 1L-18, IL-1aiIL-18, TNFa.i IL12/23, TNFa i IL-12p40, TNFa.i IL18, TNFa i IL- 23,11L1711L23.
A process to make fusidic acid cream as claimed in claim 1, wherein said cream base comprises a preservative, an acid, is co-solvent, an emulsifier and a waxy material along with purified water, and a further ingredient selected from a group consisting of a buffering agent, an anti oxidant, a chelating agent, and a humectant, or any combination thereof. 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema patentnom zahtjevu 1, naznačen time, da navedena baza kreme sadrži konzervans, kiselinu, ko-otapalo, emulgator te voštanu tvar, zajedno s vodom, prvenstveno pročišćenom vodom, 1 koja nadalje sadrži tvar koja se odabire iz skupine koja sadrži puferski agens, antioksidans, agens za keliranje i ovlaživač, ili bilo koju njihovu kombinaciju.
a gas chromatography column (22) for separating hydrogen from the gaseous mixture; 
- < kolone za plinsku hromatografiju (22) za odvajanje vodika iz plinovite smjese;
The compound for use according to embodiment 11, wherein the disease is neutrophilic asthma. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest neutrofilna astma.
splitting an image into a plurality of maximum coding units; hierarchically splitting one of the maximum coding units into one or more coding units; determining a transformation unit hierarchically split from one of the at least one coding units; extracting (1910) information about a horizontal axis direction location and a vertical axis direction location of a last significant transformation coefficient having a non-zero value and included in the transformation unit, from a received bitstream wherein the last significant transformation coefficient has last scan index according to a certain scan order among the transformation coefficients; 
kada indikator kodiranog bloka pokazuje postojanje najmanje jednog značajnog koeficijenta u transformacijskom bloku, izvlačenje (1910) informacija o lokaciji smjera vodoravne osi i lokaciji smjera okomite osi zadnjeg značajnog koeficijenta transformacije koji ima vrijednost različitu od nula i nalazi se u transformacijskom bloku, iz primljenog toka bitova naznačen time da zadnji značajni koeficijent transformacije ima zadnji indeks skeniranja prema određenom redoslijedu skeniranja između koeficijenata transformacije;
A process for preparing an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone, comprising 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 10 ppm.
Proteins and muteins produced by such deletions and/or insertions come within the purview of the present invention. 
Proteini i muteini proizvedeni takvim delecijama i/ili insercijama spadaju u područje ovog izuma.
In the following embodiments, single characteristics, in relation to specific embodiments, in reality may be interchanged with other different characteristics of other embodiments. 
U sljedećim izvedbama, pojedinačne karakteristike, u odnosu na specifične izvedbe, mogu se u stvarnosti zamijeniti s drugim različitim karakteristikama drugih izvedbi, u okviru smisla priloženih patentnih zahtjeva.
4-, 5- or 6-membered saturated heterocyclyl containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur atoms (said saturated heterocyclyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of C1-6 alkyl and haloC1-4 alkyl))}, and 
(a) Crgalkil, (b) Cs3.; cikloalkil, (c) 5-1li 6-eročlani heteroaril, koji sadrži 1, 2 ili 3 atoma dušika, atoma kisika ili atoma sumpora, ili (d) Cgqo aril (navedeni C4_19 aril može biti supstituiran s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine
The composition of item 1, wherein said functional nucleic acid targets the RNA transcript encoding a protein that contributes to drug resistance. 
Pripravak prema zahtjevu 1, gdje ta regulatorna RNA cilja RNA transkript koji kodira protein koji doprinosi otpornosti na lijekove, otpornosti na apoptozu ili neoplastičnosti.
Exemplified IC50 values of compounds of the invention: 
(54) Naziv izuma: BENZANMIDI
The method of claim 10, wherein the dsRNA is administered during an acute attack of porphyria. 
dsRNA se primjenjuje prije akutnog napada porfirije, npr., tijekom prodroma;
is phenyl substituted or unsubstituted with one or two Ra members and substituted in the ortho position with Rb; 
R/ je fenil supstituiran ili nesupstituiran sa jednim ili dva R* članova i supstituiran u orto položaju sa R*
Compound according to claim 1 (89), which compound may optionally be present in the form of a salt. 
[image] gdje taj spoj može opcijski biti prisutan u obliku soli.
In some embodiments, the crystalline compound having Formula (II) has: 
Kristalni spoj, naznačen time, da ima strukturu formule (II):
to 1 wt.-%, particularly 0.01 to 0.8 wt.-%, more preferably 0.05 to 0.3 wt.-% of iron oxide; and 
željezni oksid od 0 do 1 masenih %, posebno od 0,01 do 0,8 masenih %, najbolje od 0,05 do 0,3 masenih %; i
The antibody of claim 4, wherein the disease or disorder is selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-related disorder. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što se bolest ili poremećaj bira iz skupine koju čine: reakcija presatka prema domaćinu, autoimuna ili upalna bolest, te rak koji eksprimira CD40.
or R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C3-C6cycloalkyl ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups; 
ili R13 i R14 zajedno s atomom ugljika preko kojega su povezani formiraju fuzionirani fenilni, tienilni, pirolilni, oksazolilni, piridinilni ili (C3-C6)cikloalkilni prsten; i gdje fuzionirani fenilni, tienilni, pirolilni, oksazolilni, piridinilni ili cikloalkilni prsten opcionalno supstituiraju 1 do 3 R20 skupine;
wherein G, p, R1, R2, R3, R4, and R5 are defined as above for compounds of formula (I)′ or a pharmaceutically acceptable salt thereof. 
Spoj, ili njegova farmaceutski prihvatljiva sol, koji odgovara spoju formule (IB), naznačen time što Ri, p, Rz i Ry su definirani u skladu s patentnim zahtjevom 1.
The pharmaceutical composition according to claim 7, wherein the antigen presenting cell is a dendritic cell. 
Stanica domaćin u skladu sa zahtjevom 6, pri čemu je navedena stanica domaćin stanica koja prezentira antigen.
The invention also provides a method for the manufacture of an oil-in-water emulsion comprising steps of: (i) preparation of a first emulsion having a first average oil droplet size of 5000 nm or less, also known as a preliminary emulsion or a pre-emulsion; (ii) microfluidization of the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size; and (iii) filtration of the second emulsion using a hydrophilic membrane. 
(1) stvaranja emulzije koja sadrži skvalen koja ima prosječnu veličinu uljne kapljice od 500 nm ili manje i sadrži korake a. stvaranja prve emulzije koja ima prvu prosječnu veličinu uljne kapljice; b. mikrofluidizaciju prve emulzije da se formira druga emulzija koja ima drugu prosječnu veličinu uljne kapljice od 500 nm ili manje, koja je manja od prve prosječne veličine uljne kapljice; te (i) filtriranja druge emulzije korištenjem hidrofilne polietersulfonske membrane sa dvostrukim slojem, sa prvim slojem koji ima veličinu pora > 3pm i drugim slojem koji ima veličinu pora < 0.3um, te se time osigurava adjuvant za cjepivo.
This makes it possible for a shop to use a security system of their own choice. 
To omogućava da se u trgovini koristi zaštitni sustav po njihovom vlastitom izboru.
In detail, Figure 2c shows that grooves 6' (between two lines 6) are introduced for this purpose into the composite structure by mechanical machining along the lines 6. 
U pojedinostima, slika 2c pokazuje da su utori 6' (između dviju linija 6) uvedeni za tu svrhu u kompozitnu strukturu pomoću mehaničke strojne obrade uzduž linija 6.
administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment, wherein the daily dose administered to the patient is between 30 and 60 mg and the dose is administered once daily; and administering an acetylcholinesterase inhibitor to the patient. 
N-(2-(6-fluoro-1H-indol-3-iletil)-3-(2,2,3,3-tetrafluoropropoksi)benzilamin ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju Alzheimerove bolesti poboljšavanjem ili povećavanjem efekta inhibitora acetilkolinesteraze koja sadrži primjenjivanje djelotvorne dnevne doze navedenog spoja pacijentu koji je u potrebi takvog liječenja, pri čemu djelotvorna dnevna doza primijenjena na pacijentu iznosi između 30 1 60 mg.
to 28 unrearranged human Vλ gene segments. 
od 13 do 28 ili više segmenata gena hVλ.
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 14, wherein the anti-CTLA-4 antibody is administered about once every three weeks. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 14, gdje je rak sitnostanični rak pluća.
A method of promoting wound healing in a subject comprising administering an effective amount of laminin to the subject. 
Neka terapeutski djelotvorna količina laminina-1 za pospješivanje zacjeljivanja rane kod neke osobe, naznačena time da se taj laminin-1 primjenjuje sistemski.
Platform assembly according to one of the preceding claims, in which said at least one pivotable arm (32a, 32b) is provided with a plurality of step elements (35, 35a) which are mounted along the length of the latter and are designed to allow easier access for persons to the platform (3). 
Palubni sklop prema bilo kojem od prethodnih zahtjeva, naznačen time, da je u njemu spomenuta barem jedna stožerna ručica (32a, 32b), opskrbljena s većim brojem pragova (35, 354) koji su ugrađeni uzduž njezine duljine 1 konstruirani su za lakši pristup osobama na platformu (3).
The method of any one of clauses 61-75, wherein the subject is human. A polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:50, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO: 13, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:49. 
Protutijelo prema zahtjevu 1, zahtjevu 2, ili zahtjevu 4, naznačeno time, da obuhvaća: a) varijabilno područje jakog lanca, koje ima najmanje oko 90% identiteta sekvence od SEQ ID NO:50, SEQ ID NO:14, ili SEQ ID NO:20; 1 b) varijabilno područje slabog lanca, koje ima najmanje oko 90% identiteta sekvence od SEQ ID NO:13 ili SEQ ID NO: 19.